Department of Defense (DOD) Fiscal Year 2006 (FY06) Chronic Myelogenous Leukemia Research Program (CMLRP) Exploration - Hypothesis Development Award (EHDA)

The summary for the Department of Defense (DOD) Fiscal Year 2006 (FY06) Chronic Myelogenous Leukemia Research Program (CMLRP) Exploration - Hypothesis Development Award (EHDA) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

Department of Defense (DOD) Fiscal Year 2006 (FY06) Chronic Myelogenous Leukemia Research Program (CMLRP) Exploration - Hypothesis Development Award (EHDA): The intent of the EHDA is to support initial exploration of innovative, untested, and potentially groundbreaking concepts in CML research. Results of studies conducted through an EHDA may provide the scientific rationale upon which a new hypothesis can be based or it may provide initial principles of an innovative hypothesis. This award is designed to provide investigators with the opportunity to pursue serendipitous observations. Some gaps in supporting rationale may exist due to a lack of available information. This award is not intended to support ongoing work. Therefore, the existence of substantial preliminary data suggests that the research would be more appropriately submitted to a different award mechanism. Successfully completed EHDAs are expected to lead to high-risk, potentially high-gain future research endeavors for this and other funding agencies. Innovation and novelty of concept are important aspects of this award mechanism. It is the responsibility of the applicant to clearly and explicitly articulate how the proposed research is innovative and how the concept is novel. Because these awards are designed for preliminary investigations, projects involving human subjects or specimens will not be supported unless they are exempt under 32 CFR 219.101(b) or eligible for expedited review (32 CFR 219.110; 21 CFR 56.110). Studies that do not qualify for exempt or expedited status during review at any level will be administratively withdrawn and will not be funded.